Evidence map›Paper›PMID 33971037›Full record

Trial reportDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society2022

Efficacy of elobixibat as bowel preparation agent for colonoscopy: Prospective, randomized, multi-center study.

Daisuke Yamaguchi, Hidenori Hidaka, Takuya Matsunaga, Takashi Akutagawa, Yuichiro Tanaka, Amane Jubashi, Yuki Takeuchi, Nanae Tsuruoka, Yasuhisa Sakata, Koichi Miyahara and 8 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled TrialEquivalence Trial
In one paragraph

Trial report in Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06436833 (Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol Regimen), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06436833 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol Regimen: a Randomized Controlled Trial

TypeinterventionalSponsorDepartment of Medical Services Ministry of Public Health of ThailandRan2024 to 2024Enrolled360ConditionsBowel Preparation Solution, ColonoscopyArms2-Liter polyethylene glycol plus elobixibat, 4-Liter polyethylene glycol
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Daisuke YamaguchiDepartment of Gastroenterology, National Hospital Organization Ureshino Medical Center, Saga, Japan.ORCID https://orcid.org/0000-0001-9782-9998
Hidenori HidakaDepartment of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan.
Takuya MatsunagaDepartment of Gastroenterology, Saga-ken Medical Centre Koseikan, Saga, Japan.
Takashi AkutagawaDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Yuichiro TanakaDepartment of Gastroenterology, National Hospital Organization Ureshino Medical Center, Saga, Japan.
Amane JubashiDepartment of Gastroenterology, National Hospital Organization Ureshino Medical Center, Saga, Japan.
Yuki TakeuchiDepartment of Gastroenterology, National Hospital Organization Ureshino Medical Center, Saga, Japan.
Nanae TsuruokaDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Yasuhisa SakataDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Koichi MiyaharaDepartment of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan.
Naoyuki TominagaDepartment of Gastroenterology, Saga-ken Medical Centre Koseikan, Saga, Japan.ORCID https://orcid.org/0000-0001-6243-0776
Hiroharu KawakuboDepartment of Internal Medicine, Imari-Arita Kyoritsu Hospital, Saga, Japan.
Ayako TakamoriClinical Research Center, Saga University Hospital, Saga, Japan.
Ryo ShimodaDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Takahiro NodaDepartment of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan.
Shinichi OgataDepartment of Gastroenterology, Saga-ken Medical Centre Koseikan, Saga, Japan.
Seiji TsunadaDepartment of Gastroenterology, National Hospital Organization Ureshino Medical Center, Saga, Japan.
Motohiro EsakiDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.ORCID https://orcid.org/0000-0002-1195-0074
Saga University · JPNational Hospital Organization · JPSaga-Ken Medical Centre Koseikan · JPTakamatsu Red Cross Hospital · JPImari Arita Kyoritsu Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimElobixibat is a novel ileal bile acid transporter inhibitor. This study aimed to compare the efficacy, tolerability, and safety of the combination of elobixibat and 1 L of polyethylene glycol formulation containing ascorbic acid (PEG-Asc) solution versus the combination of sodium picosulfate and 1-L PEG-Asc solution as bowel preparation for colonoscopy.

methodsThis multi-center, randomized, observer-blinded, non-inferiority study recruited 210 outpatients who were assigned to either the elobixibat plus 1-L PEG-Asc group (group A) or the sodium picosulfate plus 1-L PEG-Asc group (group B). The quality of the bowel cleansing level was assessed by the Boston Bowel Preparation Scale (BBPS) and compared the bowel cleansing level between the groups. Data regarding bowel preparation time, patients' tolerability, and adverse events were also analyzed.

resultsData for 196 patients (99 in group A and 97 in group B) were analyzed finally. BBPS was comparable between group A and B (8.3 ± 0.9 vs. 8.3 ± 0.7; P = 0.88). Consequently, the adequate bowel preparation rate in groups A and B was 95.0% and 99.0%, respectively (-4.0%, 95% CI -9.3 to 1.5). Bowel preparation time in group A was similar to that in group B (348.2 ± 79.8 min vs. 330.8 ± 82.5 min; P = 0.13), whereas, sleep disturbance was significantly less frequent in group A than in group B (10.2% vs. 22.7%; P = 0.02).

conclusionsThe combination of elobixibat and 1-L PEG-Asc can be considered an alternative bowel preparation for colonoscopy considering the equivalent bowel cleansing effect and less frequent sleep disturbance. The Japan Registry of Clinical Trials (jRCTs41180026).

Indexed as

CatharticsDipeptidesAscorbic AcidColonoscopyHumansPolyethylene GlycolsProspective StudiesThiazepinesAscorbic AcidCatharticsDipeptideselobixibatPolyethylene GlycolsThiazepinesbowel cleansingbowel preparationcolonoscopyelobixibattolerability

Identifiers

PMID33971037
PMCPMC9290049
OpenAlexW3160768027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.